RARITAN, N.J., May 16 /PRNewswire/ -- Veridex, LLC announced today that
its licensing collaborator, Laboratory Corporation of America Holdings
(LabCorp), has commercially launched a new gene methylation test for
prostate cancer. The new assay uses the biological specificity of 'DNA
methylation' in prostate cancer, detecting the methylation of the gene
GST-Pi. Methylation is a modification of DNA that occurs primarily in
cancer. Veridex is developing the methylation markers in this tissue assay,
GST-Pi, along with other markers, for a urine-based screening test for
Prostate cancer is the leading cause of cancer death in men in the
U.S., with more than 230,000 cases diagnosed annually.
LabCorp licensed the methylation technology from Veridex in 2007.
Veridex licensed this technology from OncoMethylome Sciences, S.A. (OMS).
Veridex, LLC, a Johnson & Johnson company, develops cancer diagnostic
products that will enable earlier disease detection as well as more
accurate staging, monitoring and therapeutic selection. The company is
initially developing two complementary product lines: CellSearch(TM) assays
that identify, enumerate and characterize circulating tumor cells directly
from whole blood; and GeneSearch(TM) assays that use molecular technology
to diagnose, stage and more accurately characterize tumors. For additional
information, please visit www.veridex.com
SOURCE Veridex, LLC